Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Castle Biosciences ( (CSTL) ) has provided an update.
On Feb. 26, 2026, Castle Biosciences reported fourth-quarter and full-year 2025 results, posting 2025 revenue of $344.2 million, up 4% year over year and above guidance, with core tests DecisionDx-Melanoma and TissueCypher driving a 37% increase in total test reports. Overall growth was tempered by Medicare coverage changes for DecisionDx-SCC and the May 2025 discontinuation of IDgenetix, contributing to a shift from 2024 net income to a 2025 net loss of $24.2 million, even as the company generated $64.3 million in operating cash flow and ended the year with $299.5 million in cash and investments.
Fourth-quarter 2025 revenue rose 1% to $87.0 million, with core test volumes up 42%, but the company moved from prior-year quarterly profit to a small net loss as Adjusted EBITDA declined to $11.5 million. During late 2025, Castle bolstered its clinical and market positioning with new consensus and clinical data supporting DecisionDx-Melanoma, a meta-analysis validating TissueCypher’s risk-stratification performance, and the limited access launch of AdvanceAD-Tx, while guiding for 2026 revenue in the $340–350 million range, signaling continued focus on high-growth, high-evidence franchises despite reimbursement headwinds and portfolio pruning.
The most recent analyst rating on (CSTL) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Castle Biosciences stock, see the CSTL Stock Forecast page.
Spark’s Take on CSTL Stock
According to Spark, TipRanks’ AI Analyst, CSTL is a Neutral.
The score is anchored by mixed financial performance (profitability and free-cash-flow growth concerns) but supported by constructive technicals and clear operating momentum from raised guidance, strong test volume growth, and new product launch traction. Valuation remains a key drawback due to losses (negative P/E) and no dividend support, while reimbursement uncertainty is an important ongoing risk.
To see Spark’s full report on CSTL stock, click here.
More about Castle Biosciences
Castle Biosciences, Inc., based in Friendswood, Texas, operates in the molecular diagnostics and precision medicine industry, developing gene expression profile and tissue-based tests that guide patient care. Its core portfolio targets dermatologic and gastrointestinal diseases, led by DecisionDx-Melanoma for cutaneous melanoma and TissueCypher for Barrett’s esophagus, with an expanding presence in dermatology through offerings such as the newly launched AdvanceAD-Tx test for atopic dermatitis.
Average Trading Volume: 389,093
Technical Sentiment Signal: Buy
Current Market Cap: $873.9M
For a thorough assessment of CSTL stock, go to TipRanks’ Stock Analysis page.